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AbstrAct
Cancer molecular heterogeneity might explain the variable response of EGFR 
mutant lung adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the 
mutational status of 22 cancer genes by next-generation sequencing (NGS) in poor, 
intermediate or good responders to first-line gefitinib. Clinical outcome was correlated 
with Additional Coexisting Mutations (ACMs) and the EGFR Proportion of Mutated 
Alleles (PMA). Thirteen ACMs were found in 10/17 patients: TP53 (n=6), KRAS (n=2), 
CTNNB1 (n=2), PIK3CA, SMAD4 and MET (n=1 each). TP53 mutations were exclusive 
of poor/intermediate responders (66.7% versus 0, p=0.009). Presence of ACMs 
significantly affected both PFS (median 3.0 versus 12.3 months, p=0.03) and survival 
(3.6 months versus not reached, p=0.03). TP53 mutation was the strongest negative 
modifier (median PFS 4.0 versus 14.0 months). Higher EGFR PMA was present in 
good versus poor/intermediate responders. Median PFS and survival were longer 
in patients with EGFR PMA ≥0.36 (12.0 versus 4.0 months, p=0.31; not reached 
versus 18.0 months, p=0.59). Patients with an EGFR PMA ≥0.36 and no ACMs fared 
significantly better (p=0.03), with a trend towards increased survival (p=0.06). Our 
exploratory data suggest that a quantitative (PMA) and qualitative (ACMs) molecular 
heterogeneity assessment using NGS might be useful for a better selection of patients.
IntroductIon
Randomized clinical trials conducted in non-small-
cell lung cancer (NSCLC) carrying activating mutations 
of the epidermal growth factor receptor (EGFR) have 
clearly shown that tyrosine kinase inhibitors (TKIs) 
dramatically contribute to improve prognosis, disease 
control, symptoms and quality of life when compared to 
traditional platinum-based chemotherapy [1-5]. A recent 
meta-analysis confirmed that EGFR mutant NSCLC 
patients derived a significant progression-free-survival 
(PFS) advantage from TKIs over platinum-doublet 
chemotherapy as first-line treatment, although a significant 
differential benefit may be observed according to smoking 
status (HR for never-smokers 0.29 versus 0.54 for ever-
smokers; p < 0.007) and to the type of EGFR mutation 
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(HR for exon 19 deletion 0.25 versus 0.44 for exon 21 
substitution; p < 0.001) [6].
Therefore, the anti-EGFR TKIs gefitinib, erlotinib 
and afatinib are currently employed for the treatment of 
patients with advanced lung adenocarcinoma harboring 
EGFR activating mutations. However, the duration of 
response is variable and almost 25% of patients rapidly 
progress during treatment, many at the first disease 
assessment time-point. The question arises whether 
there are additional candidate clinical and/or molecular 
predictive factors permitting a further selection (‘super-
selection’) of patients with EGFR mutated cancers to 
implement prediction of the awaited TKIs efficacy and 
identify those patients not beneficiating from TKIs despite 
the presence of the EGFR alteration.
The onset of resistance seems to represent an 
inevitable consequence of targeted therapies in solid 
tumors. Classically, the resistance develops after an 
initial response to therapy (acquired resistance) and may 
be pharmacological (failure of delivery of the drug to its 
target) or biological, primarily deriving from the activation 
of coexisting pathways, bypassing the oncogenic 
dependency of a given driven alteration [7]. 
Although the widely validated role of the EGFR 
T790M mutation as the main mechanism of acquired 
resistance to erlotinib and gefitinib [8, 9], the reliable 
impact of this genetic alteration at diagnosis is still 
debatable, relying on contradictory data regarding its 
true incidence and clinico-biological role. The rate of 
pretreatment T790M mutation is strongly dependent on 
the sensitivity of the detection method (ranging from 2% 
to 35%) [10, 11]. Recently, Costa et al. detected a high 
frequency (65%) of coexisting EGFR T790M before 
treatment, using a highly sensitive method based on 
laser microdissection and peptide-nucleic acid-clamping 
PCR [12]. The presence of a pretreatment T790M EGFR 
mutation seems to be associated with worse clinical 
outcomes (in term of objective response and PFS) to 
EGFR TKIs compared with patients with classic EGFR 
activating alterations without any detected T790M 
mutation [13, 14]. 
Other genetic abnormalities and signaling pathways 
are currently under investigation because of their potential 
implication in the development of TKIs resistance. TP53 
represents the most frequently mutated gene in lung 
cancer, occurring in over half of adenocarcinoma, 80% 
of squamous cell carcinoma and 70% of small-cell-
lung cancer [15]. Although the prognostic role of TP53 
is still debatable, some preclinical data seem to suggest 
an intriguing predictive influence of TP53 mutation. 
In this regard, the persistent STAT3 activation has been 
observed in the residual survivor lung cancer cells both 
in vitro and in vivo under targeted TKIs, suggesting that 
early STAT3 phosphorylation may represent an important 
transcriptional programming event prior to the resurgence 
of resistant tumor survivors [16]. Moreover, TP53 and 
PTEN knowkdown synergize to activate pro-inflammatory 
interleukin-6/STAT3/nuclear factor kB signaling generating 
highly metastatic epithelial-to-mesenchymal transition-
like cancer stem cells. The constitutive activation of this 
loop leads to the suppression of SOCS3 (suppressor of 
cytokine signaling 3), a critical negative regulator of pro-
inflammatory pathways, suggesting interesting connection 
between inflammation and carcinogenesis [17]. 
Several clinical approaches can help to maintain 
the disease control in the resistance setting, including 
the use of radiation to treat isolated areas of progression 
(classically the central nervous system) and switching 
to cytotoxic chemotherapy. Moreover, novel approaches 
have already demonstrated a strong signal of activity, 
such as the development of second-generation and third-
generation inhibitors and the combination of some of 
these inhibitors with antibodies directed against the same 
target. In this continuously evolving setting, the increased 
understanding of the spectrum of resistance is mandatory 
to make progress in clinical research [18]. 
Recently, many new facets emerged, highlighting 
the fact that EGFR mutations may be potentially targeted 
even with drugs without a peculiar EGFR action, such 
as bisphosphonates [19] and ibrutinib (a Bruton tyrosine 
kinase and BMX inhibitor) [20], that have demonstrated 
activity in EGFR-mutant NSCLC cell lines, including 
erlotinib-resistant tumors. Other promising data suggest 
the fact that the EGFR mutation may represent a 
genetic biomarker predicting enhanced sensitivity to 
topoisomerase II inhibitor (such as etoposide), in response 
to a methyltransferase EZH2 inhibitor, supporting the 
biological rationale underlying the possibility of a 
combined approach with these molecules [21]. With regard 
to the hypothesis of a multi-targeted approach, another 
recent preclinical analysis demonstrated that adding 
chloroquine (acting as an autophagy inhibitor) to EGFR 
and AKT inhibition might potentially improve tumor 
responses in EGFR mutant NSCLC cells [22]. Several 
experimental approaches, such as the establishment of 
pooled short-hairpin RNAs library screen, are currently 
under investigation to identify promising drugs and 
pathways for further study in EGFR mutant NSCLC, 
including TKIs-resistant NSCLC [23]. 
Tumor heterogeneity strongly contribute to primary 
resistance. The demonstration that human cancers are 
frequently represented by a molecular mosaic of cells, 
spatially and temporally different, derived from several 
genomic studies (reviewed in [24]). Next-generation 
sequencing approaches in renal and pancreatic cancers 
have demonstrated the existence of a strong heterogeneity 
among different regions within the same tumor and 
between the primary tumor and metastasis [25, 26].
The codification of tumor heterogeneity, improving 
the understanding of the oncogenic mechanism inclusive 
of the totality of the genomic and epigenomic processes, 
may help to identify clinically relevant subgroups of 
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patients, leading to a better management of the therapeutic 
resistance to targeted agents. 
In this context, the assessment of molecular 
heterogeneity with the innovative multigene next 
generation sequencing (NGS) technology may help to 
concurrent screen for additional genetic abnormalities 
potentially deputed to drive cancer predictive testing 
for therapeutic decisions [27]. The implications for 
future research are challenging: the EGFR mutated 
dosage as well as coexisting mutations could become a 
new predictive tool for lung cancer patients and new 
technologies, such as NGS, may potentially be introduced 
in routine practice.
results
Eighteen patients from two institutions, whose 
characteristics are reported in Table 1, were studied. 
Median age was 71 years (range 37-83). Smokers were 
significantly more represented in the poor group than in the 
others (66.7% versus 10.0%, p[Fisher]=0.04). Seventeen 
patients were evaluable for PFS at least at first evaluation. 
At a median follow-up of 8 months (range: 1-33), 14 
events of progression and 7 deaths were recorded. None 
of the patients had rearrangements of the ALK gene. Six, 
3 and 8 patients were grouped as poor, intermediate and 
good responders, respectively, according to the treatment 
resistance to gefitinib and PFS (Table 2). The median PFS 
was 1.7, 6.1 and 17.3 months for poor, intermediate and 
good responders, respectively (p < 0.0001, Table 2). 
The proportion of cancer cells carrying mutated 
EGFR was calculated on the basis of the output of NGS 
analysis that furnishes the proportion of the mutated 
alleles (PMA), i.e., the number of mutated alleles over 
the total alleles analyzed. Thus, as the alleles in a cell are 
two, the proportion of cancer cells carrying a mutated 
allele is generally the double of the PMA indicated by 
NGS analysis, and referred to a cancer cellularity of at 
least 60% obtained through microdissection. As for EGFR 
mutations, median PMA was 0.2 (range 0.12-0.36), 0.16 
(range 0.15-0.65) and 0.35 (range 0.17-0.61) for poor, 
intermediate and good responders, respectively. A non-
significant trend between the good responder group and 
the 2 others was found in median PMA (0.35 versus 0.21, 
p[t-student]=0.08; p-value[Mann-Whitney]=0.16). A rate 
of 0.36 for PMA was identified at the ROC analysis as the 
best cut-off to split patients according to PFS. 
Thirteen mutations in addition to the one in EGFR 
were found in the TP53 (n=6), KRAS (n=2), CTNNB1 
(n=2), PIK3CA, SMAD4 and MET (n=1 each) gene. All 
mutations were confirmed by Sanger sequencing. None of 
the patients had more than 2 concomitant mutations. The 
association of additional mutations and prognostic groups 
are reported in Table 3 and Supplementary Table 1. TP53 
mutations (median PMA 0.45) were exclusively found 
among poor and intermediate patients and lacked in good 
responders (66.7% versus 0%, p[Fisher]=0.009) (Figure 
1, Panel A). 
A paradigmatic case of a poor responder patient 
with a clear molecular heterogeneity is shown in Figure 
1 (panels B-C) where an EGFR deletion in exon 19 
in an area of the lesion presenting a well-differentiated 
adenocarcinoma (panels B-2 and C-3) is associated 
with a concomitant TP53 mutation (R248W) in a more 
dedifferentiated area (panels B-1 and C-3); both mutations 
were confirmed by Sanger Sequencing (Figure 1, Panel 
C-4).
No significant difference according to PMA in term 
of PFS was found (PMA ≥ 0.36, median PFS 12.0 months, 
95% CI 11-13; 1-year PFS 62.0%, 2-year PFS 22.2% 
versus PMA < 0.36, median PFS 4.0 months, 95% CI 1-9; 
1-year PFS 33.0%, 2-year PFS 20.8%; p=0.31), with a 
HR of 1.53 (95% CI 0.47-5.01, p=0.48) (Figure 2, Panel 
A). With regard to OS, no significant difference according 
to PMA was found (PMA ≥ 0.36, median OS 18 months, 
95% CI 11-24; 1-year OS 83.5%, 2-year OS 41.7% versus 
PMA < 0.36, median OS not reached; 1-year OS 56.0%, 
2-year OS 55.6%; p=0.59), with a HR of 1.21 (95% CI 
0.28-5.16, p=0.79) (Figure 2, Panel B). 
A borderline significant difference in favor of the 
8 patients with ACM=0 (median PFS 12.3 months, 95% 
CI 6.1-18.6; 1-year PFS 61.5%, 2-year PFS 31.3%) in 
comparison with those 9 with a ACM≥1 (median PFS 
3.0 months, 95% CI 0.7-5.3; 1-year PFS 22.0%, 2-year 
PFS 11.1%) was found (p=0.03), with a HR of 2.88 (95% 
CI 0.92-9.02; p=0.068) (Figure 2, Panel C). With regard 
to OS, a significant difference in favor of the 8 patients 
with ACM=0 (median OS not reached, 1-year OS 88.0%, 
2-year OS 70.0%) in comparison with those 9 with a ACM 
≥ 1 (median OS 3.6 months, 95% CI 0.0-7.8; 1-year OS 
43.5%, 2-year OS 22.2%) was found (p=0.03), with a HR 
of 5.07 (95% CI 0.99-26.03; p=0.052) (Figure 2, Panel D).
A significant difference in favor of the 11 patients 
with wild type TP53 (median PFS 14 months, 95% CI 
11.0-17.0; 1-year PFS 62.5%, 2-year PFS 31.8%) in 
comparison with those 7 with a mutant TP53 (median PFS 
4.0 months, 95% CI 1.0-7.0; 1-year PFS 0%) was found 
(p=0.02), with a HR of 4.66 (95% CI 1.12-19.37; p=0.03) 
(Figure 3, Panel A). With regard to OS, no significant 
difference according the presence of p53 status was found 
(wild type TP53, median OS not reached; 1-year OS 
71.7%, 2-year OS 52.0% versus mutant TP53, median OS 
not reached; 1-year OS 58.0%, 2-year OS 57.0%; p=0.31), 
with a HR of 2.25 (95% CI 0.43-5.16, p=0.34) (Figure 3, 
Panel B). 
A significant difference in favor of the 7 patients 
with an EGFR PMA ≥ 0.36 and ACM=0 (median PFS 17.3 
months, 95% CI 11.5-23.1; 1-year PFS 70.5%, 2-year PFS 
35.7%) in comparison with those 10 with an EGFR PMA 
< 0.36 and ACM≥1 (median PFS 3.0 months, 95% CI 
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Figure 1: distribution of TP53, KRAS and CTNNB1 gene mutation according to group (p-value: Fisher’s exact test 
- panel A). A representative case of intratumor histologic and molecular heterogeneity (panel b-c). The poor responder case presented 
well-differentiated coexisting with de-differentiated areas within the same specimen (panel b; original magnifications 4x and 20x). Of 
interest, an EGFR deletion in exon 19 was observed in the well-differentiated adenocarcinoma, that was associated with a concomitant 
TP53 mutation (R248W) in the more de-differentiated area. The representation of the reads obtained by Ion Torrent sequencing, aligned to 
the reference genome as provided by the Integrative Genomics Viewer (IGV v.2.1, Broad Institute) software for the mutations in EGFR and 
TP53 genes, and the corresponding Sanger sequencing are reported. (panel c).
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Table 2: Patients’ groups according to resistance to Gefitinib and Progression-Free-Survival; 17 evaluable 
patients (log-rank p < 0.0001).
Group Definition Pts (%) Median PFs (months, 95%cI)
Poor Progression at 1st assessment 6 (35.2) 1.7 (0.1-3.2)
Intermediate Progression within 12 months 3 (17.7) 6.1 (3.0-9.2)
Good Progression ≥ 12 months or treatment ongoing 8 (47.1) 17.3 (9.0-25.5)
Pts: patients; PFS: progression-free-survival; CI: confidence intervals.
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1.0-6.0; 1-year PFS 19.4%, 2-year PFS 10%) was found 
(p=0.03), with a HR of 3.26 (95% CI 0.78-10.85, p=0.054) 
(Figure 3, Panel C). With regard to OS, a trend towards 
significance in favor of patients with an PMA ≥ 0.36 
and ACM=0 (median OS not reached; 1-year OS 86.0%, 
2-year OS 68.6%) in comparison with patients with an 
EGFR PMA < 0.36 and ACM ≥ 1 (median OS 4.0 months, 
95% CI 1-18; 1-year OS 50.5%, 2-year OS 25.0%) was 
found (p0.06), with a HR of 4.01 (95% CI 0.78-20.59, 
p=0.10) (Figure 3, Panel D).
dIscussIon 
Despite exploratory and unpowered for conclusive 
interpretations, the results reported herein indicate 
that the application of NGS technology may furnish a 
baseline genetic portrait of advanced NSCLC that gives 
information on the presence of actionable and additional 
mutations that may impair the efficacy of targeted 
therapies. A prospective validation in a large set of patients 
is required to corroborate our results. 
Our study on a series of EGFR mutant advanced 
lung cancers receiving 1st line Gefitinib suggests that the 
presence of ACM significantly decreases the expected 
benefit of TKIs. 
Among the identified ACMs, TP53 mutations 
were exclusively documented among poor/intermediate 
responders than in good responders (66.7% versus 0%, 
p=0.009), suggesting the potential implication of this gene 
in influencing the chance of response to the anti-EGFR 
agents. In lung cancer, TP53 represents the most frequently 
mutated gene, occurring in over half of adenocarcinoma, 
80% of squamous cell carcinoma and 70% of small-cell-
lung cancer [15], and, despite debated [28], it has been 
suggested as an independent marker for shorter survival 
in advanced NSCLC. A recent evidence demonstrated that 
not all TP53 mutations are equal: non-disruptive TP53 
mutations (those preserving some functional properties of 
the protein) represents an independent prognostic factor 
of shorter survival in advanced NSCLC (13.3 versus 24.6 
months; HR=2.08; p < 0.001) [29].
In contrast to EGFR-activating mutations, KRAS 
Figure 2: Progression-Free survival according to PMA (cut-off 0.36). Solid line: patients with PMA ≥ 0.36; dashed line: 
patients with PMA < 0.36 (panel A). Overall Survival according to PMA (cut-off 0.36). Solid line: patients with PMA ≥ 0.36; dashed 
line: patients with PMA < 0.36 (panel b). Progression-Free Survival according to the presence of additional coexisting mutations (ACM). 
Solid line: patients with ACM = 0; dashed line: patients with ACM ≥ 1 (panel c). Overall Survival according to the presence of additional 
coexisting mutations (ACM). Solid line: patients with ACM = 0; dashed line: patients with ACM ≥ 1 (panel d).
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mutations are usually detected in smokers, and associated 
with poor prognosis and no benefit from TKIs and 
adjuvant chemotherapy. However, some evidences are 
available regarding the coexistence of KRAS and EGFR 
mutations, raising questions about the relative values 
of these genetic abnormalities as predictors of outcome 
in NSCLC [30]. Marchetti et al. reported that patients 
carrying both mutations were resistant to TKIs and showed 
a shorter survival compared with those patients with only 
EGFR mutations, suggesting that the biological power 
determined by the presence of KRAS mutation, even if 
only in minor cellular clones, may potentially overcome 
the dependence to EGFR [31]. 
EGFR mutations are very uncommon among 
smokers and former smokers, enforcing the rationale that 
coexisting mutations may feature the disease. From a 
purely speculative point-of-view, we observed that 4 out 
of 6 TP53 mutations, KRAS mutations (n=2) and the MET 
mutation (n=1) have been detected in the smaller group 
of EGFR mutant patients that were smoker, suggesting 
a potential correlation between smoking status and the 
presence of ACMs. 
Our data may contribute to generate hypotheses 
with regard to the biological intrinsic difference between 
primary and acquired resistance, being the latest event 
supported by a series of data indicating the EGFR 
T790M mutation as the more common mechanism of 
acquired resistance to erlotinib and gefitinib [8]. Indeed, 
approximately 50-80% of rebiopses of EGFR-mutant 
patients progressing under the selective pressure of 
EGFR TKIs display this kind of mutation [8, 9]. Globally 
considered, our results support the hypothesis that TP53 
(and perhaps other tumor suppressor genes) may affect 
the efficacy of the traditional target therapy in molecularly 
addicted patients, thus triggering cell proliferation 
stimulus, and bypassing the oncogenic power of the EGFR 
pathway. 
In this population carrying ‘bad’ genetic alterations, 
Figure 3: Progression-Free survival according to the TP53 Mutation. Solid line: patients with wild type TP53; dashed line: 
patients with mutant TP53 (panel A). Overall Survival according to the TP53 Mutation. Solid line: patients with wild type TP53; dashed 
line: patients with mutant TP53 (panel b). Progression-Free Survival according to the combination of PMA (cut-off 0.36) and the presence 
of additional coexisting mutations (ACM). Solid line: patients with PMA ≥ 0.36 and ACM = 0; dashed line: patients with PMA < 0.36 
and ACM ≥ 1 (panel c). Overall Survival according to the combination of PMA (cut-off 0.36) and the presence of additional coexisting 
mutations (ACM). Solid line: patients with PMA ≥ 0.36 and ACM = 0; dashed line: patients with PMA < 0.36 and ACM ≥ 1 (panel d).
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concurrently with the classical EGFR-activating 
mutations, the employment of a combination strategy of 
chemotherapy and target agents may preserve a clinico-
biological rationale. Although no benefit was demonstrated 
for adding TKIs to chemotherapy (INTACT-1 and 2 [32, 
33], TRIBUTE [34] and TALENT trials [35]), intercalated 
erlotinib to cisplatin or carboplatin demonstrated a 
significant benefit in the context of an EGFR mutation-
positive subgroup (FASTACT-1 and 2) [36, 37], although 
these evidences warrant to be replicate in the context of 
non-asian patients’ populations. 
In addition to this ‘qualitative’ analysis exploring 
the number of ACM, we tried to determine if the 
‘quantitative’ analysis of the EGFR mutation (PMA) 
might have a role in influencing the efficacy of TKIs. 
These data allow speculating upon the exploration of 
those key processes critical to the tumor development and 
progression, as the tumor heterogeneity.
With regard to the ‘quantitative’ analysis of the 
EGFR mutation, Zhou et al. firstly hypothesized that 
the quantification of EGFR mutations might predict the 
extent of EGFR TKIs benefit, demonstrating an advantage 
in term of PFS for those patients with high abundance of 
EGFR mutations (detected concurrently with two methods 
with a different sensitivity) [38]. Our results support this 
hypothesis, although, given the limited number of patients, 
only a weak trend in favor of those patients with a high 
PMA (≥ 0.36) was found. 
Nevertheless, given the intrinsic differences in the 
adopted EGFR detection methods, the reliability of the 
observed evidences and their overall conclusions must be 
considered purely speculative for further research in this 
regard. Indeed, as recently demonstrated by Tseng et al., a 
significant portion of responses to erlotinib in EGFR wild-
type patients was related to the limitations of detection 
methods (both direct sequencing and mutant type-specific 
sensitive methods) [39].
Although no detailed study on tumor heterogeneity 
have been published in lung cancer, several data regarding 
the complexity of the molecular background of lung 
cancer are available. From the morphological perspective, 
the most recent clinico-pathological classification of lung 
adenocarcinoma identifies multiple histologic subtypes, 
frequently co-existing in the same tumor [40]. From the 
genomic standpoint, recent data demonstrate the high 
mutational rate of lung cancer, supporting the hypothesis 
of a strong heterogeneity [41, 42]. Nevertheless, a 
series of data suggest that the mutational load of lung 
adenocarcinoma in non-smoker patients (where the 
chance of detecting the EGFR mutation is the highest) 
is significantly lower [43], and that few (but critical) 
mutations may be enough to switch cells from normal to 
malignant [44]. 
While conflicting evidences exist regarding the 
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discordance rate of EGFR mutation status between 
primary tumors and metastases, a substantial consistency 
supports the lack of a reliable heterogeneity of EGFR 
mutations at the intratumor level [24]. Recently, Wright 
et al. analyzed different areas in the context of a series 
of lung adenocarcinoma specimens and found that 
KRAS and BRAF mutations were confined to high-grade 
morphological domains, while the EGFR mutations were 
identifiable through all histological subtypes in the tumor 
according to the driver status of the mutations [45]. 
Globally considered, these results suggest that 
the heterogeneity of a driver-gene mutation, such as 
that of EGFR in lung cancer is a rare molecular event. 
However, the alterations in the target gene itself (affecting 
the delivery of the drug to its target) and the concurrent 
activation or suppression of other signaling pathways 
(relevant for tumor progression and survival), may justify 
the heterogeneity in term of the clinical benefit deriving 
from the employment of target agents. 
The data emerging from our analysis support 
the potential role of the NGS technology in the deeper 
analysis of the molecular background, also in the context 
of a recognized oncogene-addicted disease, with the 
ideal aim to further improve the EGFR mutant patients’ 
selection. Our group already highlighted the basic 
contribution of NGS technique in the development of 
the translational research in the diagnostic field, able to 
provide, with limited amounts of the biological material 
(DNA), reliable quantitative and qualitative data, critical 
for the application of the tailored medicine [46]. 
Together with other emerging scientific evidences, 
our analysis may represent a proof-of-principle study 
supporting the existence of a tumor heterogeneity which, 
from now on, should be considered clinically relevant and 
deserving to be deepened for clinical validation [47]. In 
this new era of precision medicine, our study highlights 
the potential strong contribution to the understanding 
of the molecular bases of cancer yielded by NGS 
technologies, which may allow to provide a ‘qualitative’ 
(presence of ACM) and ‘quantitative’ (PMA) measure 
of the tumor heterogeneity [48]. In this regard, the found 
genetic portrait of cancer cells may mirror the underlying 
tumor heterogeneity, thus allowing to ultra-stratifying 
those EGFR mutant NSCLC patients, and estimating a 
differential clinical benefit of anti-EGFR TKIs in such 
already-selected subpopulation. 
MAterIAls And Methods
Patients
A consecutive series of patients carrying a 
sensitizing mutation of the EGFR gene, receiving first 
line gefitinib were analyzed for mutations in 22 genes 
with deep sequencing technology. In all cases, a formalin-
fixed and paraffin-embedded (FFPE) tumor excisional/
trans-bronchial biopsy was available. Patients were 
retrospectively grouped according to time to progression 
during gefitinib treatment in: poor responders (progression 
at first tumor response assessment), intermediate 
responders (progression within 12 months), and good 
responders (progression or treatment still ongoing after 12 
months). The principal aim of the study was to correlate 
the activity of gefitinib (in terms of treatment resistance 
and Progression-Free Survival, PFS) with: 1) the 
proportion of cells carrying the EGFR mutation, calculated 
on the basis of the value of the proportion of mutated 
alleles (PMA) that is derived from NGS analysis readout 
[Quantitative analysis], and 2) the presence of Additional 
Coexisting Mutations [ACM] (other than EGFR mutation) 
[Qualitative analysis]. All the samples were received 
anonymously and processed at the Molecular Pathology 
Unit of the Department of Pathology and Diagnostics of 
the University of Verona.
tissue microdissection and dnA preparation
Four 10-µm paraffin sections were manually 
microdissected to ensure that each tumor sample contained 
at least 60% of neoplastic cells. DNA was isolated using 
the QIAmp DNA FFPE tissue kit (Qiagen) and quantified 
and its quality assessed using NanoDrop® (Invitrogen 
Life Technologies; Milan, Italy) and Qubit® (Invitrogen 
Life Technologies) platforms [46, 49]. 
deep sequencing of multiplex Pcr
Amplicons. Deep sequencing was performed 
using the Ion Torrent platform (Life Technologies). 
Briefly, 10 ng of purified genomic DNA were used for 
library construction with the Ion AmpliSeq Colon and 
Lung Cancer Panel v2 (Life Technologies) that targets 
504 mutational hotspot regions of the following 22 
cancer-associated genes, in alphabetical order: AKT1, 
ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, 
FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, 
MET, NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11, 
TP53. Emulsion PCR was performed either manually 
or with the OneTouch DL system (Life Technologies). 
The quality of the obtained library was evaluated by 
the Agilent® 2100 Bioanalyzer on-chip electrophoresis 
(Agilent Technologies; Santa Clara, CA). Sequencing 
was run on the Ion Torrent Personal Genome Machine™ 
(PGM, Life Technologies) loaded with a 316 chip as 
per manufacturer’s protocol. Data analysis, including 
alignment to the hg19 human reference genome and 
variant calling, was done using the Torrent Suite 
Software v.3.2 (Life Technologies). Filtered variants were 
annotated using both the Ion Reporter software v1.2 (Life 
Oncotarget12792www.impactjournals.com/oncotarget
Technologies) and the SnpEff software v.3.0 (alignments 
visually verified with the Integrative Genomics Viewer; 
IGV v.2.1, Broad Institute) [46].
dnA sanger sequencing
To validate NGS results, KRAS (exons 2, 3), EGFR 
(exons 19, 21), TP53 (exons 5, 6, 7, 8) , and CTNNB1, 
PIK3CA, SMAD4 and MET specific PCR fragments were 
analyzed by Sanger sequencing. PCR products were 
purified using Agencourt AMPure XP magnetic beads 
(Beckman Coulter), labeled with Big Dye terminator v3.1 
(Applied Biosystems). Agencourt CleanSEQ magnetic 
beads (Beckman Coulter) were used for post-labeling 
purification. Sequence analysis was performed on an 
Applied Biosystems 3130xl Genetic Analyser.
statistics
Descriptive statistics was used to summarize 
pertinent study information. Follow-up was analyzed and 
reported according to Shuster[50]. The correlation between 
variables were analyzed according to chi-square, Student’s 
t, and Mann–Whitney (nonparametric) tests. The PMA 
value for each patient was normalized taking into account 
the rate of cellularity of malignant cells for each sample. 
The receiver operating characteristic (ROC) curve analysis 
was adopted for dichotomization of continuous variables 
according to outcome [51]. The hazard ratio (HR) and the 
95% confidence intervals (95% CI) was estimated for each 
variable using the Cox univariate model[52]. Progression-
free- and Overall-survival (PFS and OS) were calculated 
by the Kaplan-Meier product limit method from the date 
of treatment start until progression or death for any cause. 
The Log-rank and Tarone-Ware analyses were adopted 
to assess differences between curves. Significance was 
defined at the p < 0.05 level. The SPSS® (18.0) licensed 
statistical program was used for all analyses.
AcknowledGeMents, suPPort & 
FundInG
Supported by a grant of the Italian Association 
for Cancer Research (AIRC My First AIRC Grant n° 
14282, Investigator Grant n° 11631, 5X1000 n° 12182 
and 12214), and from the Italian Ministry of Education, 
Universities and Research (MIUR-FIRB RBAP10AHJB).
conFlIcts oF Interest
E.Bria has a consultancy role for Celgene, boards’ 
participation for Novartis, Astra-Zeneca, Pierre-Fabre, 
and speaker’s fee from Pfizer; S.Novello declares boards’ 
participation for Novartis, Astra-Zeneca, MSD, Boehringer 
Ingelheim, Eli Lilly, Roche and speaker’s fee from Pfizer; 
M. Milella declares boards’ participation for Celgene, 
Astra-Zeneca, Boehringer Ingelheim, and speaker’s fee 
from Pfizer, Novartis, and Celgene; A. Scarpa declares 
consultancies for Amgen, and boards’ participation for 
Novartis, Sanofi; G.Tortora has consultancy role for 
Novartis, Pfizer and GSK. No potential conflicts of interest 
were disclosed by the other authors.
reFerences
1. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti 
B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, 
Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran 
T, Insa A, et al. Erlotinib versus standard chemotherapy as 
first-line treatment for European patients with advanced 
EGFR mutation-positive non-small-cell lung cancer 
(EURTAC): a multicentre, open-label, randomised phase 3 
trial. Lancet Oncol. 2012; 13:239-246.
2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto 
I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, 
Asami K, Katakami N, Takada M, Yoshioka H, Shibata 
K, Kudoh S, et al. Gefitinib versus cisplatin plus docetaxel 
in patients with non-small-cell lung cancer harbouring 
mutations of the epidermal growth factor receptor 
(WJTOG3405): an open label, randomised phase 3 trial. 
Lancet Oncol. 2010; 11:121-128.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi 
S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita 
I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, 
Ogura T, et al. Gefitinib or chemotherapy for non-small-
cell lung cancer with mutated EGFR. N Engl J Med. 2010; 
362:2380-2388.
4. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, 
Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, 
Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, et al. 
Phase III study of afatinib or cisplatin plus pemetrexed in 
patients with metastatic lung adenocarcinoma with EGFR 
mutations. J Clin Oncol. 2013; 31:3327-3334.
5. Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli 
M, Massari F, Sperduti I, Giannarelli D, De Marinis F, 
Tortora G and Bria E. Predictors of outcome for patients 
with lung adenocarcinoma carrying the epidermal growth 
factor receptor mutation receiving 1st-line tyrosine kinase 
inhibitors: Sensitivity and meta-regression analysis of 
randomized trials. Crit Rev Oncol Hematol. 2014; 90:135-
145.
6. Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa 
SI, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell 
R, Kurata T and Ou SH. The Role of Smoking Status on 
the Progression-Free Survival of Non-Small-Cell Lung 
Cancer Patients Harboring Activating Epidermal Growth 
Factor Receptor (EGFR) Mutations Receiving First-
Line EGFR Tyrosine Kinase Inhibitor Versus Platinum 
Double Chemotherapy: A Meta-Analysis of Prospective 
Oncotarget12793www.impactjournals.com/oncotarget
Randomized Trials. Oncologist. 2015.
7. Lovly CM and Shaw AT. Molecular pathways: resistance to 
kinase inhibitors and implications for therapeutic strategies. 
Clin Cancer Res. 2014; 20:2249-2256.
8. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, 
Zakowski MF, Kris MG, Pao W, Miller VA and Ladanyi M. 
Rebiopsy of lung cancer patients with acquired resistance 
to EGFR inhibitors and enhanced detection of the T790M 
mutation using a locked nucleic acid-based assay. Clin 
Cancer Res. 2011; 17:1169-1180.
9. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski 
MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely 
GJ. Analysis of tumor specimens at the time of acquired 
resistance to EGFR-TKI therapy in 155 patients with 
EGFR-mutant lung cancers. Clin Cancer Res. 2013; 
19:2240-2247.
10. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-
Capitan A, Bertran-Alamillo J, Mayo C, Moran T, 
Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, 
Insa A, Garcia-Campelo R, Reguart N, et al. Pretreatment 
EGFR T790M mutation and BRCA1 mRNA expression 
in erlotinib-treated advanced non-small-cell lung cancer 
patients with EGFR mutations. Clin Cancer Res. 2011; 
17:1160-1168.
11. Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M 
and Riely GJ. Poor response to erlotinib in patients with 
tumors containing baseline EGFR T790M mutations found 
by routine clinical molecular testing. Ann Oncol. 2014; 
25:423-428.
12. Costa C, Molina MA, Drozdowskyj A, Gimenez-Capitan 
A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti 
B, Wei J, Moran T, Majem M, Felip E, Carcereny E, 
Garcia-Campelo R, Viteri S, Taron M, et al. The impact 
of EGFR T790M mutations and BIM mRNA expression 
on outcome in patients with EGFR-mutant NSCLC treated 
with erlotinib or chemotherapy in the randomized phase III 
EURTAC trial. Clin Cancer Res. 2014; 20:2001-2010.
13. Lee Y, Lee GK, Lee YS, Zhang W, Hwang JA, Nam BH, 
Kim SH, Kim JH, Yun T, Han JY, Kim HT and Lee JS. 
Clinical outcome according to the level of preexisting 
epidermal growth factor receptor T790M mutation in 
patients with lung cancer harboring sensitive epidermal 
growth factor receptor mutations. Cancer. 2014; 120:2090-
2098.
14. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho 
BC, Chang GC, Shih JY, Yu SL and Yang PC. Pretreatment 
epidermal growth factor receptor (EGFR) T790M mutation 
predicts shorter EGFR tyrosine kinase inhibitor response 
duration in patients with non-small-cell lung cancer. J Clin 
Oncol. 2012; 30:433-440.
15. Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson 
GA, Bueno R and Salgia R. Molecular pathways and 
therapeutic targets in lung cancer. Oncotarget. 2014; 
5:1392-1433.
16. Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, 
Fu P, Huang H, Bagai R, Jiang S, Kresak A, Howell S, 
Vasanji A, Flask CA, Halmos B, Koon H and Ma PC. 
MET-independent lung cancer cells evading EGFR kinase 
inhibitors are therapeutically susceptible to BH3 mimetic 
agents. Cancer Res. 2011; 71:4494-4505.
17. Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol 
N, Clouthier SG, Malik F, Paulson AK, D’Angelo RC, 
Korkaya S, Baker TL, Esen ES, Prat A, Liu S, Kleer 
CG, Thomas DG, et al. SOCS3-mediated regulation of 
inflammatory cytokines in PTEN and p53 inactivated triple 
negative breast cancer model. Oncogene. 2015; 34:671-680.
18. Camidge DR, Pao W and Sequist LV. Acquired resistance 
to TKIs in solid tumours: learning from lung cancer. Nat 
Rev Clin Oncol. 2014; 11:473-481.
19. Stachnik A, Yuen T, Iqbal J, Sgobba M, Gupta Y, Lu P, 
Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr 
S, Sangodkar J, Scherer T, Mujtaba S, et al. Repurposing of 
bisphosphonates for the prevention and therapy of nonsmall 
cell lung and breast cancer. Proc Natl Acad Sci U S A. 
2014; 111:17995-18000.
20. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, 
Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, 
Hofstetter WL, Swisher SG and Fang B. Selective antitumor 
activity of ibrutinib in EGFR-mutant non-small cell lung 
cancer cells. J Natl Cancer Inst. 2014; 106.
21. Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, 
Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK 
and Kim CF. EZH2 inhibition sensitizes BRG1 and EGFR 
mutant lung tumours to TopoII inhibitors. Nature. 2015; 
520:239-242.
22. Bokobza SM, Jiang Y, Weber AM, Devery AM and Ryan 
AJ. Combining AKT inhibition with chloroquine and 
gefitinib prevents compensatory autophagy and induces cell 
death in EGFR mutated NSCLC cells. Oncotarget. 2014; 
5:4765-4778.
23. Sudo M, Mori S, Madan V, Yang H, Leong G and Koeffler 
HP. Short-hairpin RNA library: identification of therapeutic 
partners for gefitinib-resistant non-small cell lung cancer. 
Oncotarget. 2015; 6:814-824.
24. Mitsudomi T, Suda K and Yatabe Y. Surgery for NSCLC 
in the era of personalized medicine. Nat Rev Clin Oncol. 
2013; 10:235-244.
25. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder 
D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey 
P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler 
A, Jones D, et al. Intratumor heterogeneity and branched 
evolution revealed by multiregion sequencing. N Engl J 
Med. 2012; 366:883-892.
26. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, 
Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, 
Velculescu VE, Kinzler KW, Vogelstein B and Iacobuzio-
Donahue CA. Distant metastasis occurs late during the 
genetic evolution of pancreatic cancer. Nature. 2010; 
467:1114-1117.
Oncotarget12794www.impactjournals.com/oncotarget
27. Liu B, Morrison CD, Johnson CS, Trump DL, Qin M, 
Conroy JC, Wang J and Liu S. Computational methods for 
detecting copy number variations in cancer genome using 
next generation sequencing: principles and challenges. 
Oncotarget. 2013; 4:1868-1881.
28. Mitsudomi T, Hamajima N, Ogawa M and Takahashi T. 
Prognostic significance of p53 alterations in patients with 
non-small cell lung cancer: a meta-analysis. Clin Cancer 
Res. 2000; 6:4055-4063.
29. Molina-Vila MA, Bertran-Alamillo J, Gasco A, Mayo-
de-Las-Casas C, Sanchez-Ronco M, Pujantell-Pastor L, 
Bonanno L, Favaretto A, Cardona AF, Vergnenegre A, 
Majem M, Massuti B, Moran T, Carcereny E, Viteri S and 
Rosell R. Nondisruptive p53 mutations are associated with 
shorter survival in advanced non-small-cell lung cancer 
patients. Clin Cancer Res. 2014.
30. Choughule A, Sharma R, Trivedi V, Thavamani A, Noronha 
V, Joshi A, Desai S, Chandrani P, Sundaram P, Utture S, 
Jambhekar N, Gupta S, Aich J, Prabhash K and Dutt A. 
Coexistence of KRAS mutation with mutant but not wild-
type EGFR predicts response to tyrosine-kinase inhibitors 
in human lung cancer. Br J Cancer. 2014; 111:2203-2204.
31. Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli 
L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo 
C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, 
Ceribelli A, Mezzetti A, Iacobelli S, et al. Clinical 
implications of KRAS mutations in lung cancer patients 
treated with tyrosine kinase inhibitors: an important role for 
mutations in minor clones. Neoplasia. 2009; 11:1084-1092.
32. Giaccone G, Herbst RS, Manegold C, Scagliotti G, 
Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, 
Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch 
SD, Wolf MK, Rennie P, et al. Gefitinib in combination 
with gemcitabine and cisplatin in advanced non-small-cell 
lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 
2004; 22:777-784.
33. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, 
Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, 
Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, 
Fandi A, et al. Gefitinib in combination with paclitaxel and 
carboplatin in advanced non-small-cell lung cancer: a phase 
III trial--INTACT 2. J Clin Oncol. 2004; 22:785-794.
34. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson 
BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies 
D, Johnson DH, Miller VA and Group TI. TRIBUTE: 
a phase III trial of erlotinib hydrochloride (OSI-774) 
combined with carboplatin and paclitaxel chemotherapy in 
advanced non-small-cell lung cancer. J Clin Oncol. 2005; 
23:5892-5899.
35. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, 
Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski 
H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, 
Vansteenkiste J, Strausz J, Manikhas GM and Von Pawel 
J. Phase III study of erlotinib in combination with cisplatin 
and gemcitabine in advanced non-small-cell lung cancer: 
the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 
2007; 25:1545-1552.
36. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, 
Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan 
M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, Chui 
W, et al. Randomized, placebo-controlled, phase II study of 
sequential erlotinib and chemotherapy as first-line treatment 
for advanced non-small-cell lung cancer. J Clin Oncol. 
2009; 27:5080-5087.
37. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera 
G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu 
Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, et 
al. Intercalated combination of chemotherapy and erlotinib 
for patients with advanced stage non-small-cell lung cancer 
(FASTACT-2): a randomised, double-blind trial. Lancet 
Oncol. 2013; 14:777-786.
38. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, 
Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, 
Wang BC, Huang YS, Wang Z and Wu YL. Relative 
abundance of EGFR mutations predicts benefit from 
gefitinib treatment for advanced non-small-cell lung cancer. 
J Clin Oncol. 2011; 29:3316-3321.
39. Tseng JS, Wang CL, Huang MS, Chen CY, Chang CY, 
Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, 
Su KY, Wu CW, Yang CT, Chen YM and Chang GC. 
Impact of EGFR mutation detection methods on the efficacy 
of erlotinib in patients with advanced EGFR-wild type lung 
adenocarcinoma. PLoS One. 2014; 9:e107160.
40. Travis WD, Brambilla E, Noguchi M, Nicholson AG, 
Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, 
Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, 
Hirsch FR, Scagliotti G, et al. International association 
for the study of lung cancer/american thoracic society/
european respiratory society international multidisciplinary 
classification of lung adenocarcinoma. J Thorac Oncol. 
2011; 6:244-285.
41. Imielinski M, Berger AH, Hammerman PS, Hernandez B, 
Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko 
A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, 
Cibulskis K, Choi K, et al. Mapping the hallmarks of lung 
adenocarcinoma with massively parallel sequencing. Cell. 
2012; 150:1107-1120.
42. Cancer Genome Atlas Research N. Comprehensive genomic 
characterization of squamous cell lung cancers. Nature. 
2012; 489:519-525.
43. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, 
Diaz LA, Jr. and Kinzler KW. Cancer genome landscapes. 
Science. 2013; 339:1546-1558.
44. Tomasetti C, Marchionni L, Nowak MA, Parmigiani G 
and Vogelstein B. Only three driver gene mutations are 
required for the development of lung and colorectal cancers. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2015; 112:118-123.
45. Wright GM, Do H, Weiss J, Alam NZ, Rathi V, Walkiewicz 
M, John T, Russell PA and Dobrovic A. Mapping of 
Oncotarget12795www.impactjournals.com/oncotarget
actionable mutations to histological subtype domains in 
lung adenocarcinoma: implications for precision medicine. 
Oncotarget. 2014; 5:2107-2115.
46. Simbolo M, Gottardi M, Corbo V, Fassan M, Mafficini 
A, Malpeli G, Lawlor RT and Scarpa A. DNA 
qualification workflow for next generation sequencing of 
histopathological samples. PLoS One. 2013; 8:e62692.
47. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, 
Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio 
S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero 
J, et al. Capturing intra-tumor genetic heterogeneity by de 
novo mutation profiling of circulating cell-free tumor DNA: 
a proof-of-principle. Ann Oncol. 2014; 25:1729-1735.
48. Mafficini A, Amato E, Fassan M, Simbolo M, Antonello 
D, Vicentini C, Scardoni M, Bersani S, Gottardi M, Rusev 
B, Malpeli G, Corbo V, Barbi S, Sikora KO, Lawlor RT, 
Tortora G, et al. Reporting tumor molecular heterogeneity 
in histopathological diagnosis. PloS one. 2014; 9:e104979.
49. Scarpa A, Sikora K, Fassan M, Rachiglio AM, Cappellesso 
R, Antonello D, Amato E, Mafficini A, Lambiase M, 
Esposito C, Bria E, Simonato F, Scardoni M, Turri G, 
Chilosi M, Tortora G, et al. Molecular typing of lung 
adenocarcinoma on cytological samples using a multigene 
next generation sequencing panel. PLoS One. 2013; 
8:e80478.
50. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 
1991; 9:191-192.
51. Hanley JA and McNeil BJ. The meaning and use of the 
area under a receiver operating characteristic (ROC) curve. 
Radiology. 1982; 143:29-36.
52. Hess KR. Graphical methods for assessing violations of the 
proportional hazards assumption in Cox regression. Stat 
Med. 1995; 14:1707-1723.
